Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis

Pharmaceutical Research

Volumn 28, Issue 1, 2011, Pages 159-165

  Daddona, Peter E ^a   Matriano, James A ^a   Mandema, Jaap ^b   Maa, Yuh Fun ^a  

^a Zosano Pharma Inc   (United States)

^b Quantitative Solutions Inc   (United States)

Author keywords

Macroflux; osteoporosis; Parathyroid hormone; pharmacodynamics; pharmacokinetics; PTH (1 34); teriparatide; transdermal microneedle patch

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MICRONEEDLE; NEEDLE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; MICROINJECTIONS; MIDDLE AGED; NEEDLES; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 78651225870     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0192-9     Document Type: Article

References (26)

1. M Cormier B Johnson M Ameri K Nyam L Libiran DD Zhang, et al. 2004 Transdermal delivery of desmopressin using a coated microneedle array patch system J Control Release 97 503 11 1:CAS:528:DC%2BD2cXkvF2itLs%3D 15212882
2. JA Matriano M Cormier J Johnson WA Young M Buttery K Nyam, et al. 2002 Macroflux® microprojection array patch technology: a new and efficient approach for intracutaneous immunization Pharm Res 19 63 70 1:CAS:528: DC%2BD38XhtVSmsbg%3D 10.1023/A:1013607400040 11837701 (Pubitemid 34075108)
3. G Widera J Johnson L Kim L Libiran K Nyam PE Daddona, et al. 2006 Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system Vaccine 24 1653 64 1:CAS:528:DC%2BD28XhsF2gsr4%3D 10.1016/j.vaccine.2005.09.049 16246466 (Pubitemid 43238242)
4. PE Daddona 2002 Macroflux® transdermal technology development for the delivery of therapeutic peptides and proteins Drug Delivery Technology 2 54 7 1:CAS:528:DC%2BD38Xmtlais7w%3D
5. G Sathyan Y-N Sun R Weyers P Daddona P Staehr S Gupta 2004 Macroflux® desmopressin transdermal delivery system: pharmacokinetics and pharmacodynamic evaluation in healthy volunteers AAPS J 6 S1 665
6. M Ameri EE Peters X Wang PE Daddona Maa Y-F 2009 Erythropoietin (EPO) coated microprojection transdermal system: pre-clinical formulation, stability and delivery AAPS J 11 S2 T2245
7. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 41 1:CAS:528:DC%2BD3MXktVSgsbw%3D 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
8. F Cosman 2008 Parathyroid hormone treatment of osteoporosis Curr Opin Endocrinol Diab Obes 15 495 501 1:CAS:528:DC%2BD1cXhtlSgsrfP
9. L Fraenkel B Gulanski D Wittink 2006 Patient treatment preferences for osteoporosis Arthritis Rheum 5 729 35 10.1002/art.22229 (Pubitemid 44619186)
10. L Fraenkel B Gulanski D Wittink 2007 Patient willingness to take teriparatide Patient Educ Couns 65 2 237 44 10.1016/j.pec.2006.08.004 16965888 (Pubitemid 46073565)
11. LJ Fraher R Avram PH Watson GN Hendy JE Henderson KL Chong, et al. 1999 Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in health humans J Clin Endocrinol Metab 8 2739 43 10.1210/jc.84.8.2739
12. CA Frolik EC Black RL Cain JH Satterwhite PL Brown-Aμgsburger M Sato, et al. 2003 Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure Bone 33 372 9 1:CAS:528:DC%2BD3sXnt1GlsLc%3D 10.1016/S8756-3282(03)00202-3 13678779 (Pubitemid 37103254)
13. R Kitazawa Y Imai M Fukase T Fujita 1991 Effects of continuous infusion of parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry Bone Miner 12 157 66 1:CAS:528:DyaK3MXlslGnsb0%3D 10.1016/0169-6009(91)90029-Y 2021707
14. JM Hock I Gera 1992 Effects of continuous and intermittent administration and inhibition of resorption of the anabolic response of bone to parathyroid hormone J Bone Miner Res 7 65 72 1:CAS:528:DyaK38XhsVCns7s%3D 10.1002/jbmr.5650070110 1532281
15. LK Potter LD Greller CR Cho ME Nuttall GB Stroup LJ Suva, et al. 2005 Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics Bone 37 159 69 1:CAS:528: DC%2BD2MXmtFSnsbo%3D 10.1016/j.bone.2005.04.011 15921971 (Pubitemid 40962422)
16. SV Komarova 2005 Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone Endocrinol 146 3589 95 1:CAS:528:DC%2BD2MXntVaiu7k%3D 10.1210/en.2004-1642 (Pubitemid 41058130)
17. V Gopalakrishnan S Hwang H Loughrey B Alexandre D Desai L Haiying, et al. 2004 Administration of ThPTH to humans using Macroflux transdermal technology results in the rapid delivery of biological active PTH J Bone Miner Res 19 Suppl 1 S460
18. F Cosman NE Lane MA Bolognese JR Zanchetta PA Garcia-Hernandez K Sees, et al. 2010 Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women J Clin Endocrinol Metab 95 151 8 1:CAS:528:DC%2BC3cXhtVGhs7c%3D 10.1210/jc.2009-0358 19858319
19. Cormier M, Neukermans AP, Block B, Theeuwes FT, Amkraut A. A device for enhancing transdermal agent delivery or sampling. EP0914178B1, 2003.
20. M Ameri PE Daddona Y-F Maa 2009 Demonstrated solid-state stability of parathyroid hormone PTH (1-34) coated on a novel transdermal microprojection delivery system Pharm Res 26 2454 63 1:CAS:528:DC%2BD1MXhtVygsb3N 10.1007/s11095-009-9960-9 20183917
21. M Ameri Y-F Maa 2009 Parathyroid hormone PTH (1-34) formulation that enables uniform coating on a novel transdermal microprojection delivery system Pharm Res 27 303 13 10.1007/s11095-009-0019-8 20013035
22. Trautman JC, Wright CT, Cormier M. Method and apparatus for coating skin piercing microneedles. US Patent 6,855,372, 2002.
23. Trautman JC, Keenan RL, Samiee AP, Lin W-Q, Cormier M, Matriano JA, et al. Apparatus and method for piercing skin with microprotrusion. US Patent 7,131,960, 2008.
24. K Chen H Nguyen J Zhu Y Shi P Prince G Scott, et al. 2006 Development and validation of a specific/sensitive/robust ELISA for quantification of human PTH (1-34) in human plasma: issues, possible solutions AAPS J 8 Suppl 2 1995
25. MR McClung J San Martin PD Miller R Civitelli F Bandeira M Omizo, et al. 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 8 1:CAS:528:DC%2BD2MXpslGgs7c%3D 10.1001/archinte.165.15.1762 16087825 (Pubitemid 41138965)
26. BM Obermayer-Pietsch F Marin EV McCloskey P Hadji J Farrerons S Boonen, et al. 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 1591 600 1:CAS:528: DC%2BD1cXht1OntLfM 10.1359/jbmr.080506 18505369